Kalvista Pharmaceuticals Inc (KALV) - Total Liabilities
Based on the latest financial reports, Kalvista Pharmaceuticals Inc (KALV) has total liabilities worth $322.93 Million USD as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kalvista Pharmaceuticals Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how Kalvista Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Kalvista Pharmaceuticals Inc (KALV) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Kalvista Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Kalvista Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Hotata Technology Group Co Ltd Class A
SHG:603848
|
China | CN¥541.36 Million |
|
Africa Oil Corp
TO:AOI
|
Canada | CA$1.59 Billion |
|
Shenzhen Chuangyitong Technology Co.Ltd.
SHE:300991
|
China | CN¥610.98 Million |
|
Sagicor Financial Company
TO:SFC
|
Canada | CA$23.66 Billion |
|
Zhejiang Meili High Technology Co Ltd
SHE:300611
|
China | CN¥3.73 Billion |
|
Huayi Compressor Co Ltd
SHE:000404
|
China | CN¥9.28 Billion |
|
Dashang Co Ltd
SHG:600694
|
China | CN¥8.26 Billion |
|
Oxford Lane Capital Corp
NASDAQ:OXLC
|
USA | $785.40 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Kalvista Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Kalvista Pharmaceuticals Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 19.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.95 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kalvista Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kalvista Pharmaceuticals Inc (2013–2025)
The table below shows the annual total liabilities of Kalvista Pharmaceuticals Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | $155.38 Million | +439.10% |
| 2024-04-30 | $28.82 Million | +29.96% |
| 2023-04-30 | $22.18 Million | +18.04% |
| 2022-04-30 | $18.79 Million | +26.77% |
| 2021-04-30 | $14.82 Million | +68.85% |
| 2020-04-30 | $8.78 Million | -58.97% |
| 2019-04-30 | $21.39 Million | -37.33% |
| 2018-04-30 | $34.14 Million | +1031.08% |
| 2017-04-30 | $3.02 Million | -7.11% |
| 2016-04-30 | $3.25 Million | -50.80% |
| 2016-03-31 | $6.60 Million | -11.72% |
| 2015-12-31 | $7.48 Million | -85.28% |
| 2015-04-30 | $50.83 Million | +351.02% |
| 2014-12-31 | $11.27 Million | -74.28% |
| 2014-04-30 | $43.81 Million | +19.01% |
| 2013-04-30 | $36.81 Million | -- |
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more